Sign In
Buy CAI
$15.67
-0.420 (-2.61%)
At Close: Jul 31, 2026
IRVING, Texas , Dec. 16, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced tha
Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect?
10:55am, Monday, 08'th Dec 2025
The consensus price target hints at a 32.8% upside potential for Caris Life Sciences,?Inc. (CAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Caris Life Sciences, Inc.’s Lock-Up Period To End on December 15th (NASDAQ:CAI)
01:12am, Monday, 08'th Dec 2025
Caris Life Sciences' (NASDAQ: CAI - Get Free Report) lock-up period is set to end on Monday, December 15th. Caris Life Sciences had issued 23,529,412 shares in its IPO on June 18th. The total size of
Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
08:30am, Thursday, 04'th Dec 2025
IRVING, Texas , Dec. 4, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced tha
The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute
08:30am, Tuesday, 02'nd Dec 2025
IRVING, Texas , Dec. 2, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that
Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class
08:30am, Friday, 21'st Nov 2025
IRVING, Texas , Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the s
Caris Life Sciences to Attend Q4 2025 Investor Conferences
08:30am, Monday, 17'th Nov 2025
IRVING, Texas , Nov. 17, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced tha
Caris Life Sciences, Inc. (CAI) Q3 2025 Earnings Call Transcript
09:01pm, Wednesday, 05'th Nov 2025
Caris Life Sciences, Inc. ( CAI ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants J. Denton - Senior VP, General Counsel & Secretary David Halbert - Chairman, CEO & Founder Bri
Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
04:05pm, Wednesday, 05'th Nov 2025
Revenue growth of 113% driven by strong performance in molecular profiling services Raises 2025 revenue guidance to $720 to $730 million, representing year-over-year growth of 75-77% IRVING, Texas , N
Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response
08:30am, Wednesday, 29'th Oct 2025
IRVING, Texas , Oct. 29, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced collaborat
Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025
08:30am, Thursday, 23'rd Oct 2025
IRVING, Texas , Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it wi
Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025
08:30am, Tuesday, 14'th Oct 2025
IRVING, Texas , Oct. 14, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, will unveil six stud
Caris Life Sciences: Impressive Growth, But Lock-Up Expiry Looms
03:11pm, Friday, 19'th Sep 2025
Caris Life Sciences stands out for its broad molecular and AI-driven cancer diagnostics but faces upcoming volatility as the IPO lock-up expires on 15 December 2025. CAI's revenue growth is robust, dr
Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®
08:30am, Friday, 15'th Aug 2025
IRVING, Texas , Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a stud
New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups
08:30am, Wednesday, 13'th Aug 2025
IRVING, Texas , Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in
